{"id":962828,"date":"2026-05-14T10:35:13","date_gmt":"2026-05-14T14:35:13","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results\/"},"modified":"2026-05-14T10:35:13","modified_gmt":"2026-05-14T14:35:13","slug":"lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/lucid-diagnostics-provides-business-update-and-reports-first-quarter-2026-financial-results\/","title":{"rendered":"Lucid Diagnostics Provides Business Update and Reports First Quarter 2026 Financial Results"},"content":{"rendered":"
\n

PR Newswire<\/p>\n<\/p><\/div>\n

\n

\n Processed 3,177 EsoGuard<\/i>
\n
\n \u00ae<\/sup>
\n <\/i>
\n tests and recognized 1Q26 revenue of $1.3 million, ending quarter with $45 million in proforma cash and a runway that extends into 2027 and past upcoming reimbursement milestones<\/i>\n <\/p>\n

\n Conference call and webcast to be held today, May 14, at 8:30 AM EDT<\/i>\n <\/p>\n

\n NEW YORK<\/span>, May 14, 2026<\/span> \/PRNewswire\/ —\u00a0Lucid Diagnostics Inc.<\/b><\/a>\u00a0(Nasdaq: LUCD)<\/b>\u00a0(“Lucid” or the “Company”) a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM) (“PAVmed”), today provided a business update for the Company and reported financial results for the first quarter ended March 31, 2026.<\/p>\n

\n

\n
\n \"Lucid
\n <\/a>\n <\/p>\n<\/p><\/div>\n

\n Conference Call and Webcast<\/b>\n <\/p>\n

The webcast will take place on Thursday, May 14, 2026, at 8:30 AM and will be accessible in the investor relations section of the Company’s website at luciddx.com<\/a>. Alternatively, to access the conference call by telephone, U.S.-based callers should dial 1-800-836-8184 and international listeners should dial 1-646-357-8785. All listeners should provide the operator with the conference call name “Lucid Diagnostics Business Update” to join.<\/p>\n

Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company’s website at luciddx.com<\/a>.<\/p>\n

\n Business Highlights <\/b>\n <\/p>\n

“Securing Medicare coverage remains our most important pending milestone, and our confidence in a positive outcome has not wavered,” said\u00a0Lishan Aklog, M.D.<\/a>, Lucid’s Chairman and Chief Executive Officer. “We continue to build commercial momentum for EsoGuard by generating consistent demand, progressing our Medicare and VA targeting efforts, and expanding engagement with health systems and commercial payors. Together with our strengthened balance sheet, these initiatives have us well-positioned to convert EsoGuard demand to revenue and further accelerate commercialization as Medicare and other key reimbursement milestones are achieved.”<\/p>\n

\n Highlights from the first quarter and recent weeks<\/b>:<\/p>\n